Blocking early complement activation prevents microglia-mediated excessive synapse loss before and during amyloid deposition. C1q localized to synapses in early AD correlates with cognitive decline; C3 knockout or CR3 deficiency protects synapses in 5xFAD mice. Annexon's ANX005 anti-C1q antibody has human CNS target engagement experience from Huntington's disease trials.
Targeted inhibition of NLRP3 inflammasome activation attenuates alpha-synuclein-driven microglial neuroinflammation, reduces IL-1β/IL-18-mediated dopaminergic neuron loss, and may slow PD progression. Oral CNS-penetrant inhibitors (dapansutrile, NT-0796) have entered Phase 2 trials, representing the most translationally viable anti-inflammatory approach in neurodegeneration.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Neuroinflammationneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
4/11
dimensions won
Complement C1q/C3 Inhibition to Prevent
7/11
dimensions won
NLRP3 Inflammasome Inhibition for Neurop
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.80
0.70
Evidence
0.78
0.72
Novelty
0.55
0.65
Feasibility
0.62
0.78
Impact
0.82
0.75
Druggability
0.75
0.80
Safety
0.52
0.65
Competition
0.65
0.70
Data
0.72
0.75
Reproducible
0.70
0.68
KG Connect
0.50
0.60
Score Breakdown
Dimension
Complement C1q/C3 Inhibition t
NLRP3 Inflammasome Inhibition
Mechanistic
0.800
0.700
Evidence
0.780
0.720
Novelty
0.550
0.650
Feasibility
0.620
0.780
Impact
0.820
0.750
Druggability
0.750
0.800
Safety
0.520
0.650
Competition
0.650
0.700
Data
0.720
0.750
Reproducible
0.700
0.680
KG Connect
0.500
0.599
Evidence
Complement C1q/C3 Inhibition to Prevent Synaptodendritis in
No evidence citations yet
NLRP3 Inflammasome Inhibition for Neuroprotection in Parkins
No evidence citations yet
Debate Excerpts
Complement C1q/C3 Inhibition to Prevent Synaptoden
4 rounds · quality: 0.75
Persona-Theorist
# Therapeutic and Mechanistic Hypotheses in Neurodegeneration
## Hypothesis 1: TREM2 Activation as a Therapeutic Strategy for Alzheimer's Disease
**Mechanism:** Loss-of-function TREM2 variants impai...
As of April 2026, I would treat these as **three translationally viable programs**, **two discovery-stage mechanisms**, and **two deprioritized concepts**.
**Feasibility Ranking**
| Rank | Hypothesi...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "NLRP3 Inflammasome Inhibition for Neuroprotection in Parkinson's Disease",
"description": "Targeted inhibition of NLRP3 inflammasome activation a...
NLRP3 Inflammasome Inhibition for Neuroprotection
4 rounds · quality: 0.75
Persona-Theorist
# Therapeutic and Mechanistic Hypotheses in Neurodegeneration
## Hypothesis 1: TREM2 Activation as a Therapeutic Strategy for Alzheimer's Disease
**Mechanism:** Loss-of-function TREM2 variants impai...
As of April 2026, I would treat these as **three translationally viable programs**, **two discovery-stage mechanisms**, and **two deprioritized concepts**.
**Feasibility Ranking**
| Rank | Hypothesi...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "NLRP3 Inflammasome Inhibition for Neuroprotection in Parkinson's Disease",
"description": "Targeted inhibition of NLRP3 inflammasome activation a...